| Name | Title | Contact Details |
|---|
Based in San Diego and founded in 2013, Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome`s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. We are a quality-focused, start-up environment where development thrives. Our culture is inspiring, fun and consists of a talented team of individuals who propose innovative ideas keeping collaboration a top priority.
Globe Labs Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.